CBD is not a cure for psoriasis, but early evidence suggests it may reduce itch and support skin barrier function in some people. Topical CBD, in particular, shows the most consistent signal in small human trials. Oral CBD has not demonstrated meaningful improvement in plaque severity in the one randomised controlled trial published so far. Here is what you need to know before trying it.
Three things to do before you start:
- Choose a topical product with a third-party Certificate of Analysis (COA) confirming cannabinoid content and the absence of heavy metals, pesticides, and microbial contaminants.
- Run a patch test and commit to an 8–12 week trial period, tracking itch, skin texture, and any reactions with photos or a simple diary.
- Tell your GP or dermatologist before you begin, especially if you take warfarin, immunosuppressants, or any medicine metabolised by the liver’s CYP450 enzyme system.
The National Psoriasis Foundation acknowledges CBD as a potential symptom-management option while emphasising that evidence remains limited and that clinician discussion is non-negotiable. A 2024 peer-reviewed review reached a similar conclusion: promising preclinical signals, but larger and better-standardised human trials are still needed. A 2025 randomised, double-blind, placebo-controlled trial of oral CBD found no significant change in PASI scores, though transient itch relief was observed at Week 8.
Table of Contents
- What does the research on CBD for psoriasis actually show?
- How does CBD interact with psoriatic skin at a cellular level?
- Which CBD product types are used for psoriasis, and what should you check on the label?
- What are the safety risks and interactions you should know about?
- Is CBD legal in the UK, and how do you verify a product is safe to buy?
- What timeline and costs should you realistically expect?
- When should you see your GP or dermatologist about CBD?
- Key studies and how strong the evidence is
- Key takeaways
- A candid perspective on CBD and psoriasis
- Hempthy’s lab-tested CBD skincare range
- Useful sources and further reading
What does the research on CBD for psoriasis actually show?
The honest answer is: more than nothing, less than a lot. The evidence base is growing, but it is still small, heterogeneous, and largely based on short-duration studies with modest sample sizes.
| Study type | Model | Outcome measured | Result direction |
|---|---|---|---|
| Split-body RCT (topical 2.5% CBD ointment, 12 weeks) | Human (n=51 target plaques) | PASI score | Statistically significant reduction on CBD side (p=0.026) |
| Oral CBD RCT (60 mg/day, 12 weeks) | Human | PASI, itch, sleep | No PASI improvement; transient itch and sleep benefit |
| Cohort studies (topical cannabinoids) | Human (small samples) | Hydration, TEWL, erythema | Modest improvements in skin barrier and scaling |
| Animal model (CBD nano-cream, UVB-induced psoriasis) | Rat | Inflammation, epidermal thickness | Reduced inflammation and hyperplasia |
| In vitro studies | Cell culture | Keratinocyte proliferation, cytokines | Antiproliferative and anti-inflammatory signals |
The strongest human evidence for topical use comes from a systematic review that identified a split-body RCT using 2.5% CBD ointment applied twice daily over 12 weeks, which produced a statistically significant but modest reduction in PASI compared with placebo. Cohort studies from 2019–2022 also reported improved skin hydration, reduced transepidermal water loss, and some reduction in erythema and scaling with CBD-containing shampoos in scalp psoriasis.
For oral CBD, the picture is less encouraging. The 2025 RCT (30 mg twice daily versus placebo) found no statistically significant difference in PASI at any time point. Itch improved at Week 8 and sleep onset latency decreased at Week 6, but neither effect was sustained by Week 12.
The main limitations across all studies: small sample sizes, short follow-up periods, widely varying formulations and concentrations, and no standardised dosing protocol. Consumer products often differ substantially from the concentrations used in trials, which makes direct comparison difficult; concentration details should be checked individually.
Evidence strength summary: Moderate for topical CBD improving itch and skin hydration in small trials; low for topical CBD reducing plaque severity; insufficient for oral CBD modifying psoriasis severity; promising but not yet clinically translatable for preclinical models.
How does CBD interact with psoriatic skin at a cellular level?
CBD does not work through a single pathway. Researchers currently point to four overlapping mechanisms that may explain its effects on psoriatic skin.
- Endocannabinoid system modulation: — Skin cells express cannabinoid receptors (CB1 and CB2) as well as non-cannabinoid receptors that CBD can influence. By modulating endocannabinoid signalling, CBD may help regulate keratinocyte proliferation, the process that drives the rapid skin cell turnover characteristic of psoriasis.
The 2024 PMC review also highlights a plausible indirect pathway: CBD’s potential to reduce anxiety and improve sleep may lessen stress-triggered flares, since psychological stress is a well-established psoriasis trigger. Stress reduction and nervous system regulation, explored further in resources on naturally supporting the nervous system, may complement topical approaches.
One important caveat: individual responses vary considerably because the endocannabinoid system differs between people. What produces noticeable itch relief in one person may produce nothing in another, even with the same product and dose.
Which CBD product types are used for psoriasis, and what should you check on the label?
Topical preparations are the most studied and, based on current evidence, the most plausible choice for skin-focused symptom management. They act locally, avoid systemic absorption at meaningful levels, and carry fewer interaction risks than oral CBD.
Topical options
Ointments, balms, and creams are the formats most commonly used in trials. The split-body RCT referenced in the systematic review used a 2.5% CBD ointment. Case reports have described use of formulations containing 15% CBG/CBD combinations. For scalp psoriasis, CBD-containing shampoos have been studied in small samples, with one formulation using 150 mg of CBD per 205 mL. These concentrations are higher than many consumer products, so checking the actual milligram content per dose matters more than the percentage figure alone.
Oral options
Oils and gummies deliver CBD systemically. The 2025 RCT used 60 mg per day (30 mg twice daily). Oral CBD may support sleep and reduce anxiety-related flares, but it has not demonstrated plaque-level improvement in controlled trials. If you are considering oral CBD, Hempthy’s broad spectrum CBD oils are third-party tested and UK FSA-compliant, with clear cannabinoid profiles on every batch COA.
What are the safety risks and interactions you should know about?
CBD is generally well tolerated, but “natural” does not mean risk-free, particularly when psoriasis is already managed with prescription treatments.
Topical reactions
Local irritation, transient redness, or a mild rash at the application site are the most commonly reported reactions. These are usually mild and resolve on stopping use. Psoriatic skin is already compromised, so any new topical product carries a slightly higher risk of irritation than it would on intact skin.
Systemic effects with oral CBD
Drowsiness, gastrointestinal upset (nausea, diarrhoea), and changes in appetite have been reported with oral CBD, particularly at higher doses. These effects are dose-dependent and tend to be mild in the ranges used in psoriasis trials.
Drug interactions
CBD is metabolised by the CYP450 enzyme system in the liver, the same pathway used by many common medicines. This creates a genuine interaction risk:
- Warfarin: CBD can increase warfarin levels, raising bleeding risk. This is a well-documented interaction requiring clinician monitoring.
- Ciclosporin and methotrexate: both are used in moderate-to-severe psoriasis and are metabolised via CYP450. Combining these with oral CBD without medical supervision is not advisable.
- Biologics: interaction data is limited, but any new supplement should be disclosed to your rheumatologist or dermatologist if you are on a biologic.
- Alcohol and sedatives: oral CBD may potentiate sedative effects.
Do/don’t summary:
- Do patch test every new topical product before full application.
- Do read the COA for contaminants, not just cannabinoid content.
- Do tell your GP or dermatologist about any CBD product you use.
- Don’t use oral CBD during pregnancy or breastfeeding.
- Don’t combine oral CBD with prescription medicines without clinician approval.
- Don’t apply topical CBD to broken, infected, or acutely inflamed skin without medical advice.
Pro Tip: If you take any prescription medicine, ask your pharmacist specifically about CYP450 interactions before starting oral CBD. It takes two minutes and could prevent a serious problem.
Children with psoriasis should not use CBD products without specialist paediatric dermatology guidance. The evidence base in children is essentially absent, and the regulatory framework for CBD in minors is not established in the UK.
Is CBD legal in the UK, and how do you verify a product is safe to buy?
CBD itself is legal in the UK as a non-psychoactive compound. Products sold as food supplements must comply with UK Food Standards Agency (FSA) guidance and contain no more than 1 mg of THC per container. Products making medicinal claims, however, require a medicines licence from the MHRA, which most consumer CBD products do not hold.
Three product classifications and what they mean
Cosmetics (topical creams, balms, shampoos): regulated by the Office for Product Safety and Standards. Cannot make medicinal claims. Must list all ingredients. No requirement to prove efficacy, only safety.
Food supplements (oils, gummies, capsules): regulated by the FSA. Must be on the FSA’s validated novel food list or have an application in progress. Cannot claim to treat, cure, or prevent disease.
Medicines: require MHRA authorisation. Epidiolex (pharmaceutical-grade CBD for epilepsy) is the only licensed CBD medicine in the UK. Consumer products are not in this category.
What timeline and costs should you realistically expect?
Antipruritic effects, when they occur, tend to appear within days to a few weeks of consistent topical use. The 2025 oral RCT observed itch improvement at Week 8, but this was not sustained at Week 12, which suggests any benefit may be transient rather than cumulative. Plaque-level changes (measurable PASI reduction) are slower and, based on current evidence, modest at best with topical CBD and absent with oral CBD in controlled trials.
Skin hydration and barrier improvements, reported in cohort studies, may be noticeable within 4–6 weeks of consistent topical use. These are arguably the most reliable outcomes to expect, and they matter for psoriatic skin regardless of whether CBD’s specific pharmacological effects are responsible.
On cost, UK retail prices for topical CBD products typically range from around £15–£25 for entry-level balms and creams to £40–£80 for higher-concentration or specialist formulations. Oral CBD oils in the ranges used in trials generally cost a moderate amount per month depending on concentration and brand. Higher concentration does not guarantee better outcomes. Formulation quality, penetration enhancers, and carrier ingredients have a greater influence on dermal delivery than the headline milligram figure alone, as preclinical nano-cream research demonstrates.
When should you see your GP or dermatologist about CBD?
Some situations warrant prompt professional review rather than a self-managed trial.
- Rapid worsening of your psoriasis — at any point during a CBD trial. Stop the product and contact your GP.
What to bring to your appointment
- Your current prescription list, including doses.
- The product COA and batch number for any CBD product you are using or considering.
- Your photo diary and itch score records from your trial period.
- Specific questions, such as: “Could CBD interact with [medicine name]?”, “Is it safe to use a topical CBD balm alongside my prescribed corticosteroid?”, or “Should I adjust my monitoring if I start oral CBD?”
Your clinician cannot advise you well without knowing what you are actually taking. Bringing the COA rather than just the product name makes that conversation far more productive.
Key studies and how strong the evidence is
Topical 2.5% CBD ointment RCT
Identified in the systematic review of cannabinoids for skin disorders, this split-body randomised controlled trial applied 2.5% CBD ointment twice daily to target plaques over 12 weeks in 51 participants. The CBD-treated side showed a statistically significant reduction in PASI (p=0.026) compared with the placebo side. Main limitation: small sample, single-centre, and the ointment base itself may have contributed to hydration improvements.
Oral CBD RCT (2026)
The Tandfonline 2025 trial is the most rigorous oral CBD study in psoriasis to date: randomised, double-blind, placebo-controlled, using 30 mg CBD twice daily. PASI did not improve significantly at any time point. Itch improved at Week 8 and sleep onset latency decreased at Week 6, but neither effect persisted to Week 12. Main limitation: single dose level tested; longer follow-up and dose-ranging studies are needed.
2024 PMC narrative review
The 2024 review synthesises preclinical and clinical evidence across multiple cannabinoids, concluding that CBD’s anti-inflammatory, antiproliferative, and antipruritic properties are biologically plausible and supported by in vitro and animal data, but that human trial evidence remains limited in scale and standardisation. It calls explicitly for larger, well-designed RCTs.
Preclinical nano-cream study
The UVB-induced psoriasis rat model study demonstrated that a CBD nano-cream formulation reduced inflammation, erythema, and epidermal hyperplasia more effectively than a standard CBD cream, supporting the hypothesis that delivery technology matters as much as cannabinoid content.
| Study | Design | Intervention | Main outcome | Conclusion |
|---|---|---|---|---|
| Topical RCT (systematic review) | Split-body RCT, n=51 | 2.5% CBD ointment, twice daily, 12 weeks | PASI score | Significant reduction on CBD side (p=0.026) |
| Oral CBD RCT (2025) | RDBPC, chronic plaque psoriasis | 30 mg CBD twice daily, 12 weeks | PASI, itch, sleep | No PASI change; transient itch and sleep benefit |
| Cohort studies (2019–2022) | Observational, small samples | Various topical cannabinoids | Hydration, TEWL, erythema | Modest skin barrier improvements |
| Nano-cream preclinical | Animal model (rat, UVB-induced) | CBD nano-cream vs standard cream | Inflammation, epidermal thickness | Nano-cream superior; supports topical delivery research |
Evidence strength (simplified GRADE):
- Topical CBD for itch and hydration: moderate (small RCT + cohort data)
- Topical CBD for plaque severity: low (modest effect in one small RCT)
- Oral CBD for psoriasis severity: insufficient (one RCT, no PASI benefit)
- Preclinical models: promising but not directly translatable
Key takeaways
CBD may ease itch and support skin barrier function in some people with psoriasis, but it is not a proven treatment for plaque severity, and oral CBD has not demonstrated disease modification in controlled trials.
| Point | Details |
|---|---|
| Topical CBD shows the strongest signal | A split-body RCT found a statistically significant PASI reduction with 2.5% CBD ointment over 12 weeks. |
| Oral CBD does not improve plaque severity | The 2025 RCT found no significant PASI change; transient itch and sleep benefits were not sustained at Week 12. |
| Always verify with a COA | Check cannabinoid content, THC level, heavy metals, and laboratory accreditation before using any product. |
| Tell your clinician before starting | CYP450 interactions (warfarin, ciclosporin, methotrexate) make clinician disclosure non-negotiable for oral CBD. |
| Hempthy’s tested topicals are a practical starting point | Hempthy’s CBD skincare range carries batch-specific COAs and complies with UK FSA guidelines. |
This article provides general information only, not medical advice. Always discuss new treatments, including CBD, with your GP or dermatologist, and check current FSA guidance for the latest regulatory position.
A candid perspective on CBD and psoriasis
The conversation around CBD for skin conditions has a tendency to run ahead of the evidence, and psoriasis is no exception. What the research actually shows is more nuanced than either the enthusiastic wellness press or the dismissive clinical sceptics suggest.
The most honest framing is this: topical CBD is a plausible adjunct for itch and skin barrier support, backed by a small but real body of human trial data. It is not a disease-modifying treatment, and anyone hoping it will replace a biologic or clear severe plaque psoriasis is likely to be disappointed. The 2025 oral RCT is particularly instructive here. A well-designed, placebo-controlled study found no meaningful plaque improvement at all. That is not a failure of CBD as a molecule; it is a signal that route of administration, formulation, and the complexity of psoriasis as an immune-mediated disease all matter enormously.
What I think gets underestimated is the skin barrier angle. Psoriatic skin is chronically compromised in terms of hydration and transepidermal water loss. A well-formulated topical that genuinely improves barrier function, whether through CBD’s specific pharmacological activity or through the quality of its carrier, has real value for people managing a condition that is as much about daily comfort as it is about plaque scores. The problem is that most consumer products are not formulated to the concentrations used in trials, and marketing claims are rarely matched by the COA.
The practical upshot: if you want to try CBD for psoriasis, start topical, verify the COA, patch test, and tell your dermatologist. That is not a hedge. It is the only approach the current evidence actually supports.
Hempthy’s lab-tested CBD skincare range
If you have read this far and you are ready to try a topical CBD product, the most important thing is not which brand you choose. It is whether the product has a current, batch-specific COA you can actually read.
Hempthy’s CBD skincare range is built around exactly that principle. Every product is third-party tested, and COAs are available by batch so you can verify cannabinoid content, confirm THC levels are within UK legal limits, and check for contaminants before the product touches your skin. The CBD Luxury Vanilla Balm is a practical starting point for anyone with psoriatic plaques: a clean formulation, available in 250 mg and 500 mg strengths, with no unnecessary fragrances or irritants. The CBD Body Lotion La Belle 250 mg is another option for broader skin coverage. Both are broad-spectrum and UK FSA-compliant.
Save your batch COA and note the batch number before you start. If you discuss your trial with your GP or dermatologist, that document makes the conversation far more useful than a product name alone. Browse the full range, pick the format that suits your skin, and start with the patch test protocol above.
Useful sources and further reading
All seven sources below are primary or authoritative references. Save the COA and batch number for any product you use, and bring them to any clinical appointment where you discuss CBD.
-
The Perspective of Cannabidiol in Psoriasis Therapy — (PMC, 2024): Peer-reviewed narrative review covering mechanisms, preclinical evidence, and clinical trial data. Concludes that promising signals exist but larger trials are needed.
-
Cannabinoids for the Treatment of Hair, Scalp, and Skin Disorders: A Systematic Review — Systematic review identifying the split-body topical RCT and cohort data on hydration and PASI. Key source for evidence grading and COA guidance.
-
Efficacy and safety of cannabidiol oil in psoriasis: a randomized, double-blind, placebo-controlled trial — (Tandfonline, 2025): The most rigorous oral CBD trial in psoriasis to date. No PASI improvement; transient itch and sleep benefits not sustained.
-
CBD for Psoriasis and Psoriatic Arthritis — (National Psoriasis Foundation): Patient-facing guidance acknowledging CBD as a potential symptom option while recommending clinician discussion.
-
CBD for Treating Plaque Psoriasis (Everyday Health): Accessible clinical summary framing CBD as a supportive option rather than a replacement for prescribed treatment.
-
Can CBD Help Treat Psoriasis? (Health Central): Expert perspectives on CBD’s anti-inflammatory and skin-hydrating properties, with a balanced assessment of current evidence limits.
